Amir Fathi, MD

Ami Fathi, MD, is the director of the leukemia program at Massachusetts General Hospital.

Articles by Amir Fathi, MD

Amir Fathi, MD, highlights how community–academic collaboration can strengthen diversity and access in clinical trials.

Community Collaboration Key to Inclusive Clinical Trial Design: Amir Fathi, MD

February 10th 2026

Community partnerships and trial design reforms can reduce travel barriers and improve underserved patient representation, said Amir Fathi, MD.

Amir Fathi, MD, discusses how geography, access, and catchment areas shape diversity in clinical trial enrollment.

Catchment Areas Shape Diversity and Access in Oncology Trials: Amir Fathi, MD

BySabrina McCrear,Amir Fathi, MD

February 9th 2026

Catchment areas, access, and partnerships influence diversity in oncology trials, Amir Fathi, MD, explains at a Boston IVBM panel.

Amir Fathi, MD, Massachusetts General Hospital

Why Education and Collaboration Are Key to Bispecific Therapy Administration: Amir Fathi, MD

ByMaggie L. Shaw,Amir Fathi, MD

October 13th 2025

Experts discuss the importance of initiating blinatumomab treatment for acute lymphoid leukemia in academic centers for optimal patient care.

Considerations for Patient Monitoring Following CAR T and Bispecific Administration: Amir Fathi, MD

ByMaggie L. Shaw,Amir Fathi, MD

August 14th 2025

Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients and their treatment team and key distinct toxicities that require vigilance.

Expertise Is Essential to Bispecific Access for Patients With Acute Leukemias: Amir Fathi, MD

ByMaggie L. Shaw,Amir Fathi, MD

July 23rd 2025

Amir Fathi, MD, discusses one of the biggest nonfinancial barriers to bispecific therapies: the expertise required to safely administer and manage them.

Amir Fathi, MD

Articles by Amir Fathi, MD

Community Collaboration Key to Inclusive Clinical Trial Design: Amir Fathi, MD

Catchment Areas Shape Diversity and Access in Oncology Trials: Amir Fathi, MD

Why Education and Collaboration Are Key to Bispecific Therapy Administration: Amir Fathi, MD

Considerations for Patient Monitoring Following CAR T and Bispecific Administration: Amir Fathi, MD

Expertise Is Essential to Bispecific Access for Patients With Acute Leukemias: Amir Fathi, MD

Latest Updated Articles

Trending on AJMC

Advances in MASLD and MASH Care Highlight Progress and Persistent Gaps

New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform

Patients With Long-Term Conditions Prefer Remote Visits for Routine Care

Employer Premiums and Deductibles Consume Significant Portion of Income in 19 States

Scaling Innovation in Advanced Multiple Myeloma Care Delivery: A Q&A With Ameet Patel, MD